出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2020/05/10 08:05:42」(JST)
| Hashimoto's encephalopathy | |
|---|---|
| Other names | Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) |
| Brain SPECT transaxial images of a patient afflicted with Hashimoto's encephalopathy. | |
| Specialty | Neurology |
Hashimoto's encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is a neurological condition characterized by encephalopathy, thyroid autoimmunity, and good clinical response to corticosteroids. It is associated with Hashimoto's thyroiditis. It was first described in 1966. It is sometimes referred to as a neuroendocrine disorder, although the condition's relationship to the endocrine system is widely disputed. It is recognized as a rare disease by the NIH Genetic and Rare Diseases Information Center.[1]
Up to 2005 there were almost 200 published case reports of this disease. Between 1990 and 2000 43 cases were published. Since that time, research has expanded and numerous cases are being reported by scientists around the world, suggesting that this rare condition is likely to have been significantly undiagnosed in the past. Over 100 scientific articles on Hashimoto's encephalopathy were published between 2000 and 2013.[2]
The onset of symptoms tends to be fairly gradual and to occur over 1-12 months.
Symptoms of Hashimoto's encephalopathy may include:
The mechanism of pathogenesis is not known but it has been hypothesized to be an autoimmune disorder, similar to Hashimoto's thyroiditis as its name suggests.
Consistent with this hypothesis, autoantibodies to alpha-enolase have been found to be associated with Hashimoto's encephalopathy.[3] Since enolase is the penultimate step in glycolysis, if it were inhibited (for example by being bound by autoantibodies) one would expect decreased energy production by each cell, leading to resulting atrophy of the affected organ.
This would occur most likely through each cell shrinking in size in response to the energy deficit (and/or in extreme situations from some cells dying via either apoptosis or necrosis, depending on location).[4] This may occur as a result of there not being enough ATP to maintain cellular functions: notably failure of the Na/K ATPase, resulting in a loss of the gradient to drive the Na/Ca antiporter which normally keeps Ca+
2 out of cells so that it does not build to toxic levels that will rupture cell lysosomes leading to apoptosis. An additional feature of a low energy state is failure to maintain axonal transport via Dynein/Kinesin ATPases, which in many diseases results in neuronal injury to both the brain and/or periphery.[5]
Very little is known about the pathology of Hashimoto's encephalopathy. Post-mortem studies of some individuals have shown lymphocytic vasculitis of venules and veins in the brain-stem and a diffuse gliosis involving gray matter more than white matter.
As mentioned above, autoantibodies to alpha-enolase associated with Hashimoto's encephalopathy have thus far been the most hypothesized mechanism of injury.[3]
Cerebrospinal fluid findings:
Thyroid hormone abnormalities are common (>80% cases):
Thyroid antibodies – both anti-thyroid peroxidase antibodies (anti-TPO, anti-thyroid microsomal antibodies, anti-M) and antithyroglobulin antibodies (anti-Tg) – in the disease are elevated but their levels do not correlate with the severity.
Electroencephalogram studies, while almost always abnormal (98% cases), are usually nondiagnostic. The most common findings are diffuse or generalized slowing or frontal intermittent rhythmic delta activity. Prominent triphasic waves, focal slowing, epileptiform abnormalities, photoparoxysmal and photomyogenic responses may be seen.[6]
A relapsing encephalopathy occurring in association with Hashimoto's thyroiditis, with high titers of anti-thyroid antibodies. Clinically, the condition may present one or more symptoms. Onset is often gradual and may go unnoticed by the patient and close associates to the patients. Symptoms sometimes resolve themselves within days to weeks, leaving a patient undiagnosed. For many other patients, the condition may result in ongoing problems with a variety of manifestations, often confusing clinicians due to the diffuse nature of symptoms.
Because most patients respond to corticosteroids or immunosuppressant treatment, this condition is now also referred to as steroid-responsive encephalopathy.
Initial treatment is usually with oral prednisone (50–150 mg/day) or high-dose IV methylprednisolone (1 g/day) for 3–7 days. Thyroid hormone treatment is also included if required.
Failure of some patients to respond to this first line treatment has produced a variety of alternative treatments including azathioprine, cyclophosphamide, chloroquine, methotrexate, periodic intravenous immunoglobulin and plasma exchange. There have been no controlled trials so the optimal treatment is not known.
Seizures, if present, are controlled with typical antiepileptic agents.
Duration of treatment is usually between 2 and 25 years. Earlier reports suggested that 90% of cases stay in remission after discontinuation of treatment; however, this is at odds with more recent studies which suggest that relapse commonly occurs after initial high-dose steroid treatment.[7][8] Left untreated, this condition can result in coma and death.
The prevalence has been estimated to be 2.1/100,000[9] with a male to female ratio of 1:4. The mean age of onset is 44 with 20% of cases presenting before the age of 18 years. Most reported cases occur during the patient's fifth decade of life.
The first case of HE was described by Brain et al. in 1966.[10] The patient was a 48-year-old man with hypothyroidism, multiple episodes of encephalopathy, stroke-like symptoms and Hashimoto's thyroiditis confirmed by elevated anti-thyroid antibodies.
| Classification | D
|
|---|
Diseases of the nervous system, primarily CNS (G04–G47, 323–349) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inflammation |
| ||||||||||||||||||||||||
| Brain/ encephalopathy |
| ||||||||||||||||||||||||
| Spinal cord/ myelopathy |
| ||||||||||||||||||||||||
| Both/either |
| ||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「橋本脳症」 |
| 比率(%) | |
| 意識障害 | 66 |
| 幻覚・せん妄 | 53 |
| 認知症 | 38 |
| 不随意運動 | 31 |
| てんかん | 29 |
| 小脳性運動失調 | 28 |
| 検査・画像項目 | 特徴 | |
| 抗甲状腺抗体 | 抗TPO抗体陽性、抗TG抗体陽性 | 52％ |
| 抗TPO抗体陽性 | 21％ | |
| 抗TG抗体陽性 | 18％ | |
| 抗TSH受容体抗体 | 9％ | |
| 甲状腺機能 | 正常 | 72％ |
| 低下（軽度） | 25％ | |
| 一過性亢進 | 3％ | |
| 血清抗NAE抗体 | 特異度 90％、感度 50％ | |
| 髄液蛋白上昇 | 45％ | |
| 脳波 | 基礎律動の徐波化 | 80％ |
| 脳MRI | 異常（ほとんどが側頭葉辺縁系病巣かびまん性白質病変） | 36％ |
| 脳血流SPECT | 低下 | 76％ |
| 臨床病型 | 鑑別疾患 |
| 急性脳症型（辺縁系脳炎含む） | 粘液水腫性脳症、ウイルス性脳炎、非ヘルペス性辺縁系脳炎、各種代謝性脳症 |
| 慢性精神病型 | 統合失調症、各種認知症、うつ病、双極性障害 |
| 小脳失調型 | 脊髄小脳変性症、急性小脳炎、薬剤性小脳失調症、急性散在性脳脊髄炎 |
| CJD様 | クロイツフェルト・ヤコブ病 |